Skip to main content
Top
Published in: AIDS and Behavior 1/2017

Open Access 01-07-2017 | Original Paper

Monitoring HIV Treatment and the Health Sector Cascade: From Treatment Numbers to Impact

Authors: Daniel Low-Beer, Michel Beusenberg, Chika Hayashi, Txema Calleja, Kimberly Marsh, Awandha Mamahit, Theresa Babovic, Gottfried Hirnschall

Published in: AIDS and Behavior | Special Issue 1/2017

Login to get access

Abstract

Although not originally part of the MDGs, HIV treatment has been at the center of global HIV reporting since 2003, marked by achievement of the target of 15 million people receiving treatment before 2015 and 18.2 million (16.1–19.0 million) by mid 2016. Monitoring of treatment has been strengthened with harmonized partner reporting and accountability with regular, annual reports. Beyond treatment numbers, increasingly measures of treatment adherence, retention and outcomes have been reported though with varying quality and completeness. However, with the sustainable development goals (SDGs), monitoring treatment is changing in three important ways. First, treatment monitoring is shifting from numbers to coverage and gaps in a cascade of services to achieve universal access. Secondly, this requires greater emphasis on disaggregated, individual level patient and case monitoring systems, which can better support linkage, retention and chronic, long term care. Thirdly, the prevention, testing and treatment cascade with a clear results chain, links treatment numbers to impact, in terms of reduced viral load, mortality and incidence. This agenda will require a greater contribution of routine impact evaluation alongside monitoring, with treatment seen as part of a cascade of services to ensure impact on mortality and incidence. In conclusion, the shift from monitoring treatment numbers to treatment linked to universal access to prevention, testing and treatment and impact on mortality and incidence, will be critical to monitor, evaluate, and improve HIV programs as part of the SDGs.
Literature
1.
go back to reference UNAIDS. How AIDS changed everything. MDG 6: 15 years, 15 lessons of hope from the AIDS response. Geneva: UNAIDS; 2015. UNAIDS. How AIDS changed everything. MDG 6: 15 years, 15 lessons of hope from the AIDS response. Geneva: UNAIDS; 2015.
2.
go back to reference WHO. Global health sector response to HIV, 2000–2015. Geneva: WHO; 2015. WHO. Global health sector response to HIV, 2000–2015. Geneva: WHO; 2015.
3.
go back to reference UNAIDS. Fast track. Understanding fast track: accelerating action to end the AIDS epidemic by 2030. Geneva: UNAIDS; 2015. UNAIDS. Fast track. Understanding fast track: accelerating action to end the AIDS epidemic by 2030. Geneva: UNAIDS; 2015.
4.
go back to reference World Health Organization. Progress on global access to HIV antiretroviral therapy: a report on “3 by 5” and beyond. Geneva: World Health Organization; 2006. World Health Organization. Progress on global access to HIV antiretroviral therapy: a report on “3 by 5” and beyond. Geneva: World Health Organization; 2006.
5.
go back to reference WHO. Prevent HIV, Test and Treat All, Progress Report on HIV Health Sector Response. Geneva: WHO; 2016. WHO. Prevent HIV, Test and Treat All, Progress Report on HIV Health Sector Response. Geneva: WHO; 2016.
6.
go back to reference World Health Organization. WHO’s contribution to universal access to universal access to HIV/AIDS prevention, treatment, care: report by the Secretariat. Geneva: WHO; 2006 (World Health Assembly document A59/39). World Health Organization. WHO’s contribution to universal access to universal access to HIV/AIDS prevention, treatment, care: report by the Secretariat. Geneva: WHO; 2006 (World Health Assembly document A59/39).
8.
go back to reference WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015.
9.
10.
go back to reference WHO. Consolidated strategic information guidelines for HIV in the health sector. Geneva: WHO; 2015. WHO. Consolidated strategic information guidelines for HIV in the health sector. Geneva: WHO; 2015.
11.
go back to reference Fox MP, Rosen SJ. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. Acquir Immune Defic Syndr. 2015;69:98–108.CrossRef Fox MP, Rosen SJ. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. Acquir Immune Defic Syndr. 2015;69:98–108.CrossRef
12.
go back to reference Bekker LG, Venter F, Cohen K, Goemare E, Van Cutsem G, Boulle A, et al. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther. 2014;19(Suppl 3):105–16.CrossRefPubMed Bekker LG, Venter F, Cohen K, Goemare E, Van Cutsem G, Boulle A, et al. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther. 2014;19(Suppl 3):105–16.CrossRefPubMed
13.
go back to reference INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.CrossRef INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.CrossRef
14.
go back to reference Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to ART care in sub-Saharan Africa: a systematic review. AIDS. 2012;26:2059–67.CrossRefPubMed Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to ART care in sub-Saharan Africa: a systematic review. AIDS. 2012;26:2059–67.CrossRefPubMed
16.
go back to reference Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett T. The new role of antiretrovirals in combination HIV prevention: a mathematical modeling analysis. AIDS. 2013;27:447–58.CrossRefPubMed Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett T. The new role of antiretrovirals in combination HIV prevention: a mathematical modeling analysis. AIDS. 2013;27:447–58.CrossRefPubMed
17.
go back to reference Medley A, Bachanas P, Grillo M, Hasen N, Amanyeiwe U. Integrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence. J Acquir Immune Defic Syndr. 2015;68(Suppl 3):S286–96.CrossRefPubMedPubMedCentral Medley A, Bachanas P, Grillo M, Hasen N, Amanyeiwe U. Integrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence. J Acquir Immune Defic Syndr. 2015;68(Suppl 3):S286–96.CrossRefPubMedPubMedCentral
Metadata
Title
Monitoring HIV Treatment and the Health Sector Cascade: From Treatment Numbers to Impact
Authors
Daniel Low-Beer
Michel Beusenberg
Chika Hayashi
Txema Calleja
Kimberly Marsh
Awandha Mamahit
Theresa Babovic
Gottfried Hirnschall
Publication date
01-07-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue Special Issue 1/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1754-1

Other articles of this Special Issue 1/2017

AIDS and Behavior 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.